Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

VERNALIS PLC (VER)

1
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
02/23/2015 02/24/2015 02/25/2015 02/26/2015 02/27/2015 Date
46.375(c) 45.5(c) 46.125(c) 49(c) 47.25 Last
40 051 208 176 1 014 806 150 356 30 771 Volume
-1.33% -1.89% +1.37% +6.23% -3.57% Change
More quotes
Company
Vernalis Plc is a research and development stage pharmaceutical company.The company provides pharmaceutical products for a range of medical disorders.It focuses on de novo fragment and structure based drug discovery and pre clinical and clinical development.The group has one marketed product,... 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Financials ( GBP)
Sales 2015 17,6 M
EBIT 2015 -17,6 M
Net income 2015 -13,9 M
Finance 2015 52,1 M
Yield 2015 -
Sales 2016 -
EBIT 2016 -
Net income 2016 -
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016 -
Capi. / Sales 2015 9,35x
Capi. / Sales 2016 -
Capitalization 217 M
More Financials
Latest news on VERNALIS PLC
02/26 VERNALIS : licenses proprietary adenosine receptor antagonist technology, includ..
02/26 VERNALIS : Enters Licence Deal With US-Based Biotechnology Firm
02/26 VERNALIS : Licenses Proprietary ARA Technology
02/10 VERNALIS : Posts Narrowed Loss On Dollar Strength And Lower Costs
02/10 VERNALIS : Unaudited interim results for the periods ended 31 December 2014
02/10 VERNALIS : Unaudited interim results for periods to 31/12/14
02/10 VERNALIS : Unaudited Interim Results for the Periods Ended 31 December 2014
02/06 VERNALIS : Notice of Interim Results for the Periods Ended 31 December 2014
More news
Sector news Biotechnology & Medical Research - NEC
09:44a ISIS PHARMACEUTICALS : Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx P..
09:31a ISIS PHARMACEUTICALS : Reports Financial Results and Highlights for 2014
08:01a QUINTILES TRANSNATIONAL : CEO to Present at Barclays Global Healthcare Conferenc..
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF